Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure.

Current heart failure reports - 1 Dec 2017

Parikh Kishan S, Piccini Jonathan P

Abstract excerpt

PURPOSE OF REVIEW: We explore the pharmacogenomics of the beta-blocker bucindolol by discussing relevant beta-1 adrenergic receptor (ADRB1) polymorphisms and recent beta-blocker studies. Through this, we will understand how bucindolol may help patients with atrial fibrillation and heart failure with reduced ejection fraction (AF-HFrEF), which carries poor prognosis. RECENT FINDINGS: Retrospective study of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Antagonists
Share to Atrial Fibrillation
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heart Failure

Share to Pharmacogenetics

Share to Propanolamines

Share to Receptors, Adrenergic, beta-1

Share to Stroke Volume

Source

Identifiers

PMID: 28975475
DOI: 10.1007/s11897-017-0364-6

Genes

ADRB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure.PMID 28975475Read ↗

Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype.Semantic proximity Read ↗

Combinatorial Pharmacogenetic Interactions of Bucindolol and β1, α2C Adrenergic Receptor PolymorphismsSemantic proximity Read ↗

Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation.Semantic proximity Read ↗

A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.Semantic proximity Read ↗

A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.Semantic proximity Read ↗

Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure.Semantic proximity Read ↗

The future of pharmacogenetics in the treatment of heart failure.Semantic proximity Read ↗

Pharmacogenetics of heart failure: evidence, opportunities, and challenges for cardiovascular pharmacogenomics.Semantic proximity Read ↗

Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients.Semantic proximity Read ↗

State of play of pharmacogenetics and personalized medicine in heart failure.Semantic proximity Read ↗

Pharmacogenomics of heart failure.Semantic proximity Read ↗

Renin-angiotensin-aldosterone system (RAAS) pharmacogenomics: implications in heart failure management.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.